Comparative Pharmacology
Head-to-head clinical analysis: DURYSTA versus LATANOPROSTENE BUNOD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURYSTA versus LATANOPROSTENE BUNOD.
DURYSTA vs LATANOPROSTENE BUNOD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaglandin analog; selective FP receptor agonist that increases uveoscleral outflow of aqueous humor.
Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2α analog. It is hydrolyzed by esterases in the eye to latanoprost acid and nitric oxide. Latanoprost acid increases uveoscleral outflow of aqueous humor via FP receptor agonism, while NO enhances trabecular meshwork outflow via soluble guanylate cyclase activation.
One intracameral implant (10 mcg) administered in the study eye by a qualified ophthalmologist. A second administration may be performed if necessary, at least 3 months after the initial implant.
One drop (approximately 1.5 mcg) in the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine."
Clinical Note
moderateNot applicable due to local ocular administration with minimal systemic exposure; bimatoprost systemic half-life is approximately 45 minutes after intravenous administration.
The terminal elimination half-life of latanoprostene bunod is approximately 17 minutes for the active metabolite (latanoprost acid) after topical ocular administration. This short half-life reflects rapid systemic clearance, consistent with once-daily dosing for intraocular pressure reduction.
Minimal systemic absorption; no data on specific routes of elimination; expected to be primarily excreted via renal and biliary routes in small amounts.
The primary route of elimination is via the kidneys, with approximately 88% of the dose excreted in urine as metabolites; fecal excretion accounts for about 6%, and the remainder is excreted via other routes. Renal excretion of unchanged drug is minimal.
Category C
Category A/B
Prostaglandin Analog
Prostaglandin Analog
Balsalazide + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Balsalazide."